ECCO 2025 at a glance
As ECCO 2025 approaches, LucidQuest summarizes the must-know updates in IBD therapies, biomarkers, real-world evidence, digital health, and AI/ML so you can navigate the meeting with focus.
📅 Build your schedule around the topics that interest you. 📥 Download the ECCO 2025_Preview_by_LucidQuest
Dive deeper
Key Topics From ECCO 2025 Scientific Presentations
Phase 2/3 Data Highlight New Therapies
-
T&H diet shows better tolerance (88% vs. 52%) than EEN in CD.
-
Ustekinumab reduces secondary IMID risk (HR = 0.63, p < 0.001) vs. anti-TNFs.
-
Infliximab trough levels in PFCD remain suboptimal, indicating dose optimization needs. 🏹💉
Long-Term Safety & Efficacy
-
Risankizumab, Etrasimod, Upadacitinib maintain remission over 4 years.
-
Vedolizumab + Upadacitinib yield higher early clinical (63.4%) and endoscopic (61.5%) responses vs. monotherapy. 🩺
Next-Gen Targeted Therapies
-
Guselkumab delivers superior UC remission (27.6% vs. 6.5%, p < 0.001), emerging as a first-line option for moderate–severe disease. 🚀
Predictive Biomarkers & Personalized Medicine
-
HLA-DQA1, fecal TNF, and tryptophan metabolism refine risk stratification, highlighting multi-omics potential. 🔬
Microbiome–Disease Link
-
Key strains predict relapse; Porphyromonas gingivalis worsens UC via barrier disruption.
-
ML-based microbial biomarkers (AUC = 0.971) enhance diagnosis and therapy success. 🦠
Global Trends & Economic Burden
-
IBD incidence rises in Asia/Africa (UC +30%).
-
Brazilian CD prevalence up 288%, though biologics reduce hospitalizations (59%) and surgeries (55%). 🌎
Patient-Reported Outcomes & Digital Health
-
Nurse-led PROMOTION study boosts PRO response to 71.8% (p = 0.004).
-
Risankizumab maintenance lowers urgency, pain, and fatigue, reinforcing long-term UC efficacy. 🏥
Artificial Intelligence and Machine Learning at ECCO 2025
AI in Endoscopy
-
ML enhances UC scoring, cutting non-informative frames by 80%.
-
Clip-level ML shows patchy inflammation distribution. 🤖
AI in Histological Analysis
-
AI-based Nancy scoring (AUROC = 0.95) reclassifies 22/76 “inactive” UC cases, suggesting underdiagnosis. 🩺
AI in IBD Imaging and Prediction
-
NLP-based classification (AUC up to 0.955) streamlines inflammation/stenosis detection.
-
AI-assisted partial endoscopy (κ = 0.944) matches full colonoscopy. 🖥️
AI in Precision Therapy and Epidemiology
-
Body composition–based AI predicts anti-TNF response (AUC = 0.785).
-
ML identifies Crohn’s up to 10 years pre-diagnosis (AUC = 0.70 adults, 0.68 kids). 🏆
📅 Build your schedule around the topics that interest you.
📥 Download the ECCO 2025_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.